Xeris Biopharma Holdings, Inc. (XERS) Financial Analysis & Valuation | Quarter Chart
Xeris Biopharma Holdings, Inc. (XERS)
XERSPrice: $6.28
Fair Value: 🔒
🔒score
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis,... more
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializi... more
Description
Shares
| Market Cap | $1.08B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | John Shannon |
| IPO Date | 2018-06-21 | CAGR | 0.93% |
| Employees | 394 | Website | www.xerispharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 46812614.8% | Total Yield | 46812614.8% |
XERS chart loading...
Fundamentals
Technicals
| Enterprise Value | $769.02M | P/E Ratio | -62.8 |
| Forward P/E | 16.07 | PEG Ratio | — |
| P/S Ratio | 0.01 | P/B Ratio | -0.01 |
| P/CF Ratio | -0.01 | P/FCF Ratio | -0.01 |
| EPS | $-0.1 | EPS Growth 1Y | -76.86% |
| EPS Growth 3Y | -89.86% | EPS Growth 5Y | -96.66% |
| Revenue Growth 1Y | 42.05% | Gross Margin | 0.81% |
| Operating Margin | -0.04% | Profit Margin | -0.13% |
| ROE | 1.14% | ROA | -0.1% |
| ROCE | -0.04% | Current Ratio | 1.95 |
| Quick Ratio | 1.24 | Cash Ratio | 0.62 |
| Debt/Equity | -13.32 | Interest Coverage | -0.33 |
| Altman Z Score | 0.54 | Piotroski Score | 4 |